Outlook Therapeutics Seeks CMS Reimbursement Code Ahead of LYTENAVA Launch
Outlook Therapeutics’ CMS reimbursement application marks a key commercial milestone for LYTENAVA and $OTLK ahead of its planned 2026 U.S. launch.
Connect Biopharma Shares Jump 25% on Positive Phase 2 COPD Data
Connect Biopharma shares jumped 25% after positive Phase 2 COPD data for rademikibart, putting biote…
Kodiak Sciences Nearly Triples to $90: Can a $5.64 Billion Valuation Hold?
Kodiak Sciences’ jump from roughly $32 to $90 creates a sharp clash between biotech momentum and the…
Eli Lilly Builds Q4 Momentum With Positive Ebglyss Phase 3b Results
Positive Ebglyss and retatrutide trial updates give Eli Lilly’s pipeline broader support heading int…
Capricor Therapeutics Jumps 12.8% as Analysts Raise Stakes Ahead of FDA Decision
CAPR traded 12.84% higher after B. Riley upgraded the stock to Buy, sharpening focus on deramiocel a…
AstraZeneca’s US Lung Cancer Filing Puts Its HUTCHMED Partnership in Focus
AstraZeneca’s FDA application for a HUTCHMED-linked lung cancer treatment marks a pipeline milestone…
Lantheus Stock May Be 14% Undervalued After BRAVNETSA FDA Approval
Lantheus’ BRAVNETSA approval may support a 14% fair-value gap, but SPARROW timing and capital needs …
AbbVie’s Parkinson’s Drug Approval Fails to Lift Shares as ABBV Slips Nearly 1%
AbbVie won FDA approval for Juvmo, yet ABBV slipped nearly 0.8% as investors weighed expectations, m…
Egetis Shares Jump 13.2% After FDA Approves First MCT8 Deficiency Treatment
Egetis shares rose 13.2% after FDA approval of EMCITATE, putting rare-disease strategy and U.S. comm…
FDA Expands Eli Lilly’s Olumiant Label to Adolescents With Severe Alopecia
The FDA approved Eli Lilly’s once-daily Olumiant for adolescents with severe alopecia areata, expand…